These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
961 related articles for article (PubMed ID: 28298550)
1. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550 [TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
3. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
4. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
5. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470 [TBL] [Abstract][Full Text] [Related]
6. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R; Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878 [TBL] [Abstract][Full Text] [Related]
8. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461 [TBL] [Abstract][Full Text] [Related]
9. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
10. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902 [TBL] [Abstract][Full Text] [Related]
13. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
17. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051 [TBL] [Abstract][Full Text] [Related]
19. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820 [TBL] [Abstract][Full Text] [Related]